---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-275871"
form_type: "8-K"
ticker: "PRLD"
cik: "0001678660"
company_name: "Prelude Therapeutics Inc"
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T21:18:57.403572+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Prelude Q3 net loss $19.7M; cash into 2027; JAK2/KAT6A IND timelines set

## Summary
- Q3 net loss $19.7M ($0.26/sh) vs $32.3M ($0.43) YoY; cash $58.2M at Sep 30.
- Received $60M upfront from Incyte for exclusive option on JAK2V617F inhibitor; cash runway into 2027.
- JAK2V617F JH2 inhibitor IND filing expected Q1 2026; oral KAT6A degrader IND mid-2026.
- Preclinical data for JAK2 inhibitor and mCALR DAC accepted for oral ASH Dec 2025 presentations.
- Expanded AbCellera collaboration; additional license payment received in Oct 2025.

## SEC filing metadata
- accession: 0001193125-25-275871
- form_type: 8-K
- ticker: PRLD
- cik: 0001678660
- company_name: Prelude Therapeutics Inc
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1678660/000119312525275871/0001193125-25-275871-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1678660/000119312525275871/prld-20251112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-275871
- JSON: https://secwatch.observer/filing/0001193125-25-275871.json
- Plain text: https://secwatch.observer/filing/0001193125-25-275871.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.